Clinical trialPhase 1 / Phase 2Completed

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Combination of Antiangiogenic Therapy Using the mTOR-inhibitor RAD001 and Low Dose Chemotherapy for Locally Advanced and/or Metastatic Pancreatic Cancer - a Dose Finding Study

NCT00560963 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Finished, no results posted
Phase: Phase 1 / Phase 2
Status: Completed
Study type: Interventional
Start: October 2007
Expected end: January 2011
Enrollment: 21 participants
Sites: 5
Primary outcomes: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of everolimus in combination with Gemcitabine
Sponsor: Industry
Results posted: No
Last update: 21 December 2020

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A dose finding study in locally advanced and/or metastatic pancreatic cancer patients